×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MRSN – mersana therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MRSN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/7
04:05 pm
mrsn
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2/6
07:33 am
mrsn
Mersana Therapeutics, Inc. (NASDAQ: MRSN) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
Medium
Report
Mersana Therapeutics, Inc. (NASDAQ: MRSN) is now covered by analysts at William Blair. They set an "outperform" rating on the stock.
1/30
08:15 am
mrsn
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference [Yahoo! Finance]
Medium
Report
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference [Yahoo! Finance]
1/30
08:00 am
mrsn
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
Medium
Report
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
1/10
08:13 pm
mrsn
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $4.00 price target on the stock, down previously from $7.00.
High
Report
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $4.00 price target on the stock, down previously from $7.00.
1/10
06:02 am
mrsn
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
High
Report
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
1/10
06:00 am
mrsn
Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer
High
Report
Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer
12/17
07:11 am
mrsn
Alphina Therapeutics Strengthens Management Team with Appointment of Marc Damelin, Ph.D. as Chief Scientific Officer [Yahoo! Finance]
Medium
Report
Alphina Therapeutics Strengthens Management Team with Appointment of Marc Damelin, Ph.D. as Chief Scientific Officer [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/13/2024
07:00 am
mrsn
mersana therapeutics, inc.
BEAT
Report
19.5%
mersana therapeutics, inc.
8/13/2024
07:00 am
mrsn
mersana therapeutics, inc.
MISS
Report
-3.6%
mersana therapeutics, inc.
5/9/2024
06:59 am
mrsn
mersana therapeutics, inc.
BEAT
Report
-30.2%
mersana therapeutics, inc.
2/28/2024
07:00 am
mrsn
mersana therapeutics, inc.
BEAT
Report
13.6%
mersana therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/14
06:16 pm
mrsn
Form SCHEDULE 13G/A Mersana Therapeutics, Filed by: Venrock Healthcare Capital Partners III, L.P.
Low
Report
Form SCHEDULE 13G/A Mersana Therapeutics, Filed by: Venrock Healthcare Capital Partners III, L.P.
2/5
01:24 pm
mrsn
Form SCHEDULE 13G/A Mersana Therapeutics, Filed by: BlackRock, Inc.
Low
Report
Form SCHEDULE 13G/A Mersana Therapeutics, Filed by: BlackRock, Inc.
2/5
08:08 am
mrsn
Form 8-K Mersana Therapeutics, For: Feb 05
High
Report
Form 8-K Mersana Therapeutics, For: Feb 05
1/17
07:28 pm
mrsn
Form 4 Mersana Therapeutics, For: Jan 15 Filed by: Mandelia Ashish
Medium
Report
Form 4 Mersana Therapeutics, For: Jan 15 Filed by: Mandelia Ashish
1/17
07:27 pm
mrsn
Form 4 Mersana Therapeutics, For: Jan 15 Filed by: Protopapas Anna
Medium
Report
Form 4 Mersana Therapeutics, For: Jan 15 Filed by: Protopapas Anna
1/17
07:25 pm
mrsn
Form 4 Mersana Therapeutics, For: Jan 15 Filed by: Lowinger Timothy B
Medium
Report
Form 4 Mersana Therapeutics, For: Jan 15 Filed by: Lowinger Timothy B
1/17
07:21 pm
mrsn
Form 4 Mersana Therapeutics, For: Jan 15 Filed by: Huber Martin H. Jr.
Medium
Report
Form 4 Mersana Therapeutics, For: Jan 15 Filed by: Huber Martin H. Jr.
1/17
07:20 pm
mrsn
Form 4 Mersana Therapeutics, For: Jan 15 Filed by: DeSchuytner Brian
Medium
Report
Form 4 Mersana Therapeutics, For: Jan 15 Filed by: DeSchuytner Brian
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/8
Mersana Therapeutics secures $65M capital raise [Seeking Alpha]
33.5%
1/16 Mersana Therapeutics Inc (NASDAQ: MRSN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 22.7%
2/8 Mersana Therapeutics Inc (NASDAQ: MRSN) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 14.9%
11/27 Form 8-K Mersana Therapeutics, For: Nov 26 12.6%
2/28 Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.7%
2/18 Mersana Therapeutics to Present at Upcoming Investor Conferences 9.1%
12/23 Form SC 13G Mersana Therapeutics, Filed by: Venrock Healthcare Capital Partners II, L.P. 9.1%
5/9 Form 10-Q Mersana Therapeutics, For: Mar 31 8.3%
10/10 Mersana Therapeutics Inc (NASDAQ: MRSN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.1%
11/6 Form 8-K Mersana Therapeutics, For: Nov 06 7.0%
1/16 Mersana Therapeutics Inc (NASDAQ: MRSN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 22.7%
2/8 Mersana Therapeutics Inc (NASDAQ: MRSN) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 14.9%
11/27 Form 8-K Mersana Therapeutics, For: Nov 26 12.6%
2/28 Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.7%
2/18 Mersana Therapeutics to Present at Upcoming Investor Conferences 9.1%
12/23 Form SC 13G Mersana Therapeutics, Filed by: Venrock Healthcare Capital Partners II, L.P. 9.1%
5/9 Form 10-Q Mersana Therapeutics, For: Mar 31 8.3%
10/10 Mersana Therapeutics Inc (NASDAQ: MRSN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.1%
11/6 Form 8-K Mersana Therapeutics, For: Nov 06 7.0%
TOP News Decliners
3/30
Form 8-K Mersana Therapeutics, For: Mar 30
-15.5%
3/14 Mersana Therapeutics Inc (NASDAQ: MRSN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.50 price target on the stock. -13.8%
12/28 Mersana Therapeutics Inc (NASDAQ: MRSN) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -12.8%
3/12 Mersana Therapeutics Inc (NASDAQ: MRSN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.7%
8/10 Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -9.3%
4/9 Form 424B5 Mersana Therapeutics, -9.1%
4/29 Mersana Therapeutics to Host Conference Call Announcing First Quarter 2020 Financial Results and Business Updates -8.9%
4/20 Form DEF 14A Mersana Therapeutics, For: Jun 12 -8.8%
6/1 Mersana Presents Interim Phase 1 Data for XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting -8.1%
6/12 Form 8-K Mersana Therapeutics, For: Jun 07 -7.8%
3/14 Mersana Therapeutics Inc (NASDAQ: MRSN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.50 price target on the stock. -13.8%
12/28 Mersana Therapeutics Inc (NASDAQ: MRSN) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -12.8%
3/12 Mersana Therapeutics Inc (NASDAQ: MRSN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.7%
8/10 Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -9.3%
4/9 Form 424B5 Mersana Therapeutics, -9.1%
4/29 Mersana Therapeutics to Host Conference Call Announcing First Quarter 2020 Financial Results and Business Updates -8.9%
4/20 Form DEF 14A Mersana Therapeutics, For: Jun 12 -8.8%
6/1 Mersana Presents Interim Phase 1 Data for XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting -8.1%
6/12 Form 8-K Mersana Therapeutics, For: Jun 07 -7.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: